LungArchives
Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer
Lung 4 min.
The standard treatment for stage III non-small cell lung cancer (NSCLC) is platinum-based concurrent chemoradiotherapy (CCRT), followed by durvalumab (anti-programmed death ligand-1 [PD-L1] antibody) maintenance therapy [1]. However, the 5-year survival rate for unresectable NSCLC remains unsatisfactory...
Minimally invasive segmentectomy for non-small cell lung cancer (NSCLC): a comparative analysis of robotic and thoracoscopic approaches
Lung 5 min.
Lung segmentectomy is an anatomical resection that removes one or more bronchopulmonary segments while preserving healthy surrounding tissue. Unlike lobectomy, which involves resecting an entire lobe, segmentectomy targets smaller anatomical units, offering a lung-sparing alternative for early-stage...
Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
Lung 1 min.
The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. The study sought...
Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): significance in diagnosis and treatment in Asian patients
Lung 6 min.
The emergence of actionable biomarkers and targeted therapy changed the treatment paradigm in advanced non-small cell lung cancer (NSCLC) [1, 2]. Epidermal growth factor receptor (EGFR) is present in about a third of all patients with advanced non-squamous NSCLC, with higher prevalence in Asians, non-smokers,...
Comparison of segmentectomy and lobectomy for non-small cell lung cancer with visceral pleural invasion
Lung 4 min.
Surgical resection is currently the mainstay of curative treatment for early-stage non-small cell lung cancer (NSCLC). Visceral pleural invasion (VPI) has a significant impact on staging and prognosis and is an important factor in determining surgical strategy [1, 2]. Previous studies demonstrated that...
